首页 >
法规速递
-
Page: Non-clinical development and evaluation of microbiome-based medicinal products - Scientific guideline-2026/3/2
2026-03-03查看详情 > -
Page: Changing the labelling and package leaflet (Article 61(3) notifications)-2026/3/27
2026-03-30查看详情 > -
Document: Template for response to list of questions/list of outstanding issues: Quality / Non-clinical / Clinical-2026/5/12
2026-05-13查看详情 > -
Document: Appendix 1: Acceptable intakes established for N-nitrosamines-2026/6/24
2026-06-25查看详情 > -
Biosimilar and Interchangeable Biosimilar Products: Considerations for Container Closure Systems and Device Constituent Parts-2026/7/31
2026-08-02查看详情 > -
注射用两性霉素B脂质体生物等效性研究技术指导原则-2022/11/25
2022-11-25查看详情 > -
国家药监局关于发布仿制药参比制剂目录（第六十七批）的通告（2023年第22号）-2023/5/6
2023-05-06查看详情 > -
Regulatory and procedural guideline: European Medicines Agency post-authorisation procedural advice for users of the centralised procedure: document with track changes (updated)-2023/11/13
2023-11-15查看详情 > -
Document: Applications for new human medicines under evaluation: January 2025-2025/1/16
2025-01-17查看详情 > -
关于将酒石酸艾格司他胶囊纳入《以患者为中心的罕见疾病药物研发试点工作计划（“关爱计划”）》试点项目的公示-2025/2/21
2025-02-24查看详情 >
